Artemisia capillaris, which belongs to the Asteraceae family and the genus Artemisia, has been reported to exert inhibitory effects on diabetes, cancer and inflammation. In this study, in order to enhance the bioactivity potential of the leaves of Artemisia by Ganoderma lucidum mycelium, we prepared aqueous samples of Artemisia capillaris (Ac) leaves, Ganoderma lucidum (Gl) and aqueous fractions produced by the solid fermentation of Ganoderma lucidum on Artemisia capillaris leaves (afAc/Gl). Thereafter, we evaluated whether these samples have potential to attenuate inflammation-related symptoms in an amimal model of 2,4-dinitrofluorobenzene (DNFB)-induced atopic dermatitis. We found that afAc/Gl exhibited enhanced anti-inflamamatory activity following the solid fermentation process when compared with Ac or Gl on ear thickness, ear epidermal thickness and eosinophil infiltration in the skin tissues. The expression of nitric oxide (NO) synthases (NOSs) was measured by immunohistochemical staining. The results revealed that afAc/Gl decreased endothelial NOS and inducible NOS expression compared with the DNFB group, while neuronal NOS expression was not altered. By comparing NO production, we found that as opposed to Ac, afAc/Gl has potential to inhibit atopic dermatitis-related symptoms during the inflammatory event. As regards matrix metalloproteinase (MMP) expression patterns, afAc/Gl exerted potent inhibitory activity on the mRNA expression of MMP-2, -7, -9, -12, -14 and -19. Taken together, these results suggest that the solid state fermentation of Ac by Gl is an effective strategy to obtaining useful ingredients which are converted into valuable compounds during an atopic inflammatory insult.
Introduction
Atopic dermatitis is a skin disease with inflammatory, pruritic, chronic and relapsing symptoms and up to 20% of children are affected worldwide (1) . Atopic dermatitis is caused by unbalanced Th cells as Th2 cykokine increase, and is characterized by increased serum levels of IgE and peripheral eosinophilia (2) . Atopic dermatitis is well known as a chronic inflammatory disease, as it is caused by defective skin barrier function (3) and by the overexpression of inflammatory factors, such as cyclooxygenase-2 (COX-2) and inducible nitric oxide (NO) synthase (iNOS) (4) . Inflammatory processes are mediated through COX-2 and iNOS which generate NO and prostaglandin E 2 (5) . Macrophages, generally stimulated by lipopolysaccharide (LPS), also play major role in inflammation as a self-defense against innate immunity (6) .
Artemisia capillaris (A. capillaris; Ac) belongs to the family of Asteraceae and the genus Artemisia, which has been traditionally used as a medicinal herb and as a hepatoprotective, analgesic and antipyretic agent in Asia (7) . It also has been reported to have various functions against inflammation (6) , cancer (8) , Helicobacter pylori infection (9) and hepatotoxicity (10) . Recently, it was reported that 70% ethanol extract of Ac exerted inhibitory effects on atopic dermatitis-like skin lesions via the downregulation of serum histamine content and IgE expression (11) . In our laboratory, we have been eager to screen out useful plant resources for industrial purposes. In order to improve the bioavailability of natural ingredients, the fermentation technique had been used to enhance their activity, as well as to reduce their toxicity. Even though submerged fermentation is a more common process in microbial production, solid fermentation is more effective as regards productivity and bioconversion (12) . Moreover, it has been well documented that solid fermentation is a simple, easy and economical process which requires limited facilities; however, it is a timeconsuming process compared to liquid fermentation. It has been previously demonstrated that solid state fermented black bean by Aspergillus species (13) , and solid fermented wheat grain by Grifola species enhanced the antioxidant activity of black bean (13, 14) . Chickpea, which is a type of bean, has also been shown to exert anti-hyperglycemic effects following solid-state bioconversion by Rhizopus oligosporus (15) . These are good examples that non-degradable biomass can be converted into valuable biomaterials by solid fermentation using fungi, yeast and bacteria, which can enhance the bioavailability of natural resources.
The present study demonstrated that Ac, following solid state fermentation with Ganoderma lucidum (G. lucidum; Gl), had the potent potential to inhibit atopic dermatitis-related symptoms in an animal model of 2,4-dinitrofluorobenzene (DNFB)-induced atopic dermatitis. To the best of our knowledge, there are no available studies to date examining the effects of Ac following solid fermentation on atopic dermatitis. Solid fermentation is considered an innovative process with good pharmaceutical potential as the antioxidant capacity of Ac increases following solid fermentation with various mycelia. In this study, we focused on Gl, which has great potential to improve the antioxidant capacity, in order to investigate whether Ac has the potential to alleviate inflammation-related symptoms before and after solid fermentation.
We hypothesized that following the solid fermentation Ac leaves with Gl will result in the production of active compounds which may have the potential to enhance the anti-inflammatory effects of Ac on atopic dermatitis.
Materials and methods
Materials and reagents. DNFB (Sigma, St. Louis, MO, USA; dissolved in polyethylene glycol) was sterile filtered using a syringe filter 0.45 µm (Pall Life Sciences, Port Washington, NY, USA) and used for the induction of atopic dermatitis in mice. Polyethylene glycol (P3265; Sigma) was used as a vehicle for application on the mouse ear surface.
Animal care. C57BL/6 mice (6 weeks of age, male, weighing between 20 and 23 g, 5 mice per group) were purchased from Samtaco Korea (Osan, Korea). The mice were allowed to acclimatize for 7 days in an air-ventilated animal room at a temperature of 22+1˚C and a humidity of 65+5% under a 12-h light/dark cycle. All animal experiments were carried out according to the guidelines of the Committee of the International Association for the Study of pain Research and Ethical Issues (16) and following the approval (permission no. KNU-2014-0145) of the KNU Animal Ethics Committee (Chair, Dr Hee-Kyung Jin).
Solid fermentation of Gl on Ac leaves. The plant was obtained from a local supplier at Andong, Korea and Gl was donated from Farmbios Co., Ltd. (Daegu, Korea). Fermentation was carried out as previously described by Shin et al (17) , with a slight modification. In brief, the mycelia of Gl was cultured on potato dextrose broth (Difco Co., Detroit, MI, USA) at 25˚C in a shaking incubator for 20 days. A. capillaris was dried and autoclaved at 121˚C for 20 min (Fig. 1A) , and 10 g of the grown mycelia with potato dextrose agar medium was then adapted into 200 g of A. capillaris. Even though the mycelia were in liquid potato dextrose agar medium, they were rapidly dried (<5% moisture) and the mixed materials were subjected to solid fermentation. This fermentation was performed at 25˚C for 2 weeks, and we finally observed the white fruit body of G. lucidum (Fig. 1B) . The fermented product was extracted with distilled water ina shaking incubator in at 25˚C for 24 h, and it was then lyophilized (MCTD85; Il-Shin, Gyeonggi-do, Korea) following filtration. The voucher specimens of the plant and fermented samples have been deposited in the Laboratory of Enzyme Biotechnology, Kyungpook National University, Daegu, Korea.
Animal model of DNFB-induced atopic dermatitis.
We created an animal model of DNFB-induced atopic dermatitis as previously described, with some modifications (18, 19) . In brief, 50 µl of 0.5% (w/v) DNFB solution (Sigma; dissolved in polyethylene glycol) was applied on the abdominal skin of mice for primary sensitization. At 5 days following sensitization, 20 µl 0.2% (w/v) DNFB was applied to the ear skin at 3-day intervals. Treatment with 20 µl of the samples (final concentration, 100 µg/ml) was carried out 1 day following exposure to DNFB (Fig. 1C) . In total, DNFB and the treatment samples were applied 4 times and we observed inflammation-related symptoms, such as swelling or scabs on the mouse ear surface. At 2 days following the final sample application, the mice were sacrificed and the ear organs were isolated. The experimental groups were divided into the NT (vehicle alone) group, DNFB (DNFB treatment alone) group, Ac (DNFB treatment and thereafter application of aqueous fraction of Ac) group, Gl (DNFB treatment and thereafter application of aqueous fraction of Gl) group and afAC/Gl (DNFB treatment and thereafter application of aqueous fraction produced by solid fermentation of Gl on Ac) group, as described in Fig. 1 .
Hematoxyline and eosin (H&E) staining and immunohistochemistry.
H&E staining was carried out as previously described (20) . In brief, the ear tissues were entirely cut and fixed with 10% formalin solution in phosphate-buffered saline (PBS) for at least 12 h. In order to maintain the linear shape of the ear tissue, it was placed between 2 coverslips following formalin fixation. The organ sections were fixed in paraffin lengthwise and transferred onto slides. Subsequently, 3% hydrogen peroxide in methanol solution was applied to prevent endogenous peroxidase activity and the slides were stained with H&E (HHS32 and HT110332΄ Sigma). To perform immunohistochemical analysis, each slide was treated with a 10% normal goat serum for 1 h, and the slides were then incubated overnight at 4˚C with rabbit anti-mouse antibodies against iNOS (ab15326), endothelial NOS (eNOS; ab5589) and neuronal NOS (nNOS; ab72428) (all from Abcam, Cambridge, MA, USA), as previously described (21) . To observe the immunohistochemical sections, a Nikon microscope and camera (Eclipse, TE-2000U; Nikon, Tokyo, Japan) were used.
Evaluation of atopic dermatitis-related symptoms.
Various factors of atopic responses (ear swelling, ear epidermal swelling, total cell count and eosinophil count) were measured on the H&E-stained sections. First, ear thickness or ear epidermal thickness was calculated using ImageJ software [1.48 version, National Institutes of Health (NIH)]. Next, total cell and eosinophil counts were determined. Due to the of unique morphology of eosinophils, total cells were counted first, and then eosinophil cells were observantly counted under a microscope (Eclipse, TE-2000U; Nikon) at x400 magnification.
Measurement of NO levels and cytotoxicity assay. NO production and cell viability were assayed using the RAW264.7 cell line, which was obtained from American Type Culture Collection (Cat. no. TIB-71; Manassas, VA, USA). The cells were seeded as 5x10 4 cells/well with 200 µl of medium [10% fetal bovine serum (FBS; Hyclone, Lagan, UT, USA) in Dulbecco's modified Eagle's medium (DMEM; Hyclone)] in a 96-well plate. The cells were pre-incubated in a 96-well plate for 4 h, and this was followed by the addition of lipopolysaccharide (LPS, 1 mg/ml, L2880; Sigma) and the treatment samples and incubation at 5% CO 2 , 37˚C for 24 h. To detect NO production, 100 µl of supernatants from the cell culture plate were moved to a new 96-well plate, and 100 µl of Griess reagent (G4410; Sigma) were then added. According to the reaction between NO product and Griess reagent, the color changed yellow to pink and the absorbance was then measured at 520 nm on a spectrophotometer (VICTOR3; Perkin Elmer, Wellesley, MA, USA). To measure the cytotoxicity of the treatment samples, cell culture medium was removed from a 96-well cell culture plate which had remained following NO assay. Subsequently, 100 µl of DMEM with 0.5 mg/ml methylthiazolyldiphenyl-tetrazolium bromide (MTT, M2128) solution were added followed by incubation for 30 min. The supernatants were removed and the plates were washed twice with PBS. Thereafter, the produced formazan crystals from the MTT solution were dissolved into DMSO and cell viability was assessed by measuring the absorbance at 595 nm on a spectrophotometer.
Reverse transcription-polymerase chain reaction (PCR) for mRNA expression. To determine the effects of A. capillaris on mRNA expression in RAW264.7 cells, the cells were seeded at 5x10 6 cells/well in a 6-well plate (BD Falcon, NJ, USA). The cells were treated with LPS (1 µg/ml) for 4 h and with the sample extracts at 30 µg/ml for 5 h. Following the removal of the cell supernatant, RNA was isolated using TRIzol ® reagent (Invitrogen, New York, NY, USA). Total RNA was reverse transcribed into cDNA using RT-PCR master mix (Qiagen, Valencia, CA, USA). cDNA was amplified with manufactured primers as follows: matrix metalloproteinase (MMP)-2 forward, ACCAGAACACCATCGAGACC and reverse, AAA GCATCATCCACGGTTTC; MMP-7 forward, GAGTGCC AGATGTTGCAGAA and reverse, CCATCAAAGGGGAA GCTGT; MMP-9 forward, GGGTTTCTGTCCAGACCAAG and reverse, GGATGCCGTCTATGTCGTCT; MMP-12 forward, TTGATGGCAAAGGTGGTACA and reverse, CGAAATGTGCTGGGGTTAAG; MMP-14 forward, CCGCCATGCAAAAGTTCTAT and reverse, GCCTTGAT CTCAGTCCCAAA, MMP-19 forward, GACATTCGCCT CTCTTTCCA and reverse, AGGTCCCCTCAGTCCAGAGT; and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) forward, ATGTTCCAGTATGACTCCAC and reverse, GCCAAAGTTGTCATGGATGA (Bioneer, Daejeon, Korea) and detected using 1% agarose gel by ChemiDOC™ XRS + Molecular Imager (Bio-Rad, Hercules, CA, USA). The band density from the esults of the PCR product was calculated using Image Lab software (5.0 version; Bio-Rad).
High-performance liquid chromatography photodiode array (HPLC-PDA) analysis. Cholorogenic acid and caffeic acid were analyzed as described in a previous study (11) . HPLC analysis was performed using a Waters 2695 HPLC system (Waters Co., Milford, MA, USA) fitted with a binary pump, an autosampler, a column oven and a PDA detector. The HPLC system was monitored by a computer equipped with Empower software (Waters Co.). Chromatographic separation was performed on a HYPERSIL ODS C18 column (250x4. Statistical analysis. Data are expressed as the means ± standard deviation. Statistical significance was determined by one-way ANOVA with Tukey's post-hoc test using the SPSS 21.0 program (SPSS, Inc., Chicago, IL, USA). The critical level for significance was set at P<0.05.
Results and Discussion
Effects of aqueous fraction produced by the solid fermentation of Gl on Ac (afAc/Gl) on a mouse model of DNFB-induced atopic dermatitis. To determine the inhibitory effects of afAc/Gl against atopic dermatitis-related symptoms, we established a mouse model of DNFB-induced atopic dermatitis (Fig. 1C) and analyzed the data. First, we conducted an observation of the ear surface, as atopic dermatitis is characterized by the appearance of inflammation. In the DNFB-treated mice, due to scratching of the ears, we found that the skin had swelled and scabs had formed on the DNFB-applied tissue sites. However, we found that the sample-treated mice, particularly those treated with afAc/Gl, exhibited less scratching behavior, ear swelling and scabs. At the end of the experimental period, the ears of the mice in the DNFB-treated group had become twisted in appearance due to the inflammatory response in the body, whereas in the sample-treated groups, the ears of the mice were only moderately twisted in appearance; in particular, the ears of the mice in the afAc/Gl-treated group were almost similar in appearance to those of the control group (Fig. 2A) . To obtain more reliable positive data, we assessed ear thickness on H&E-stained slides using ImageJ software. The paraffinembedded ear tissues exhibited incremental thickness form the edge of the outer site of the ear towards the inside; therefore, we selected the same section and averaged the length for further investigation. The whole appearance of the paraffin-embedded ear tissue was observed under a microscope at a magnification of x40 (Fig. 2B) , and half the ear tissue on cartilage was observed at x400 magnification (Fig. 2C) . The results revealed that ear thickness in the afAc/Gl-treated mice decreased by 32%, while that of the Gl-treated mice decreased by 13%; ear thickness in the Ac-treated mice did not differ compared to the NT group (Fig. 2D) . In addition, ear epidermal thickness in the afAc/Gl-treated mice decreased by 37%, which was the most signicant among the sample treatment groups.
In atopic dermatitis, eosinophil numbers depend on various factors, such as platelet-activating factor (PAF), cytokines, leucotrienes and prostanoids (22) . Therefore, eosinophil numbers can be predicted by increased itching, which may not be observed in normal skin. As shown by our results, eosinophils were observed at limited numbers in the control group; however, the eosinophil numbers were markedly inreased in the DNFB-treated group. Treatment with afAc/Gl decreased the number of eosinophils by approximately 74% compared to those of the DNFB-treated group (Fig. 2D) . These results suggest that the solid fermentation of afAc by Gl may be used to enhance the anti-inflammatory potential in atopic dermatitis.
afAc/Gl extract exhibits enhanced anti-inflammatory potential in atopic dermatitis by reducing eNOS expression in vivo.
We then investigated whether eNOS plays a pivotal role in downregulating the protein expression in skin tissues exposed to DNFB. Protein expression was determined by immunohistochemical microscopic analysis at a magnification of x400 (Fig. 3A) . We first counted the number of eNOS-positive cells on overall paraffin-embedded ear tissues. The results revealed that the tissue of the afAc/Gl-treated mice did not exhibit any eNOSpositive cells, as opposed to the tissue of the DNFB-, Ac-or Gl-treated mice (Fig. 3A, compare the number of arrowheads) . Thus, eNOS expression was increased by DNFB and afAc/Gl treatment attenuated this effect. As shown in Fig. 3B , the number of eNOS-positive cells in the afAc/Gl-treated group was significantly decreased compared to the DNFB group. Treatment with Ac also decreased the numer of eNOS-positive cells, but not as significantly as afAc/Gl. Similarly, iNOS was also excessively expressed in the DNFB-treated group (Fig. 3C and D) . However, only treatment with afAc/Gl significantly decreased the number of iNOS-positive cells. The expression of iNOS did not exhibit any significant changes between the groups (data not shown).
NO is an important molecule in body homeostasis as a secondary signal mediator, and it is synthesized from L-arginine by NOS [nNOS (NOS1), iNOS (NOS2) and eNOS (NOS3)]. iNOS is mainly well-known as an inflammatory mediator with a function similar to COX-2, which is generally upregulated in inflammation (23) (24) (25) . It has been well-documented that iNOS is upregulated during the inflammatory response in various cancer cells exposed to LPS, while nNOS (NOS1) and eNOS (NOS3) are expressed constitutively (23) . iNOS is a key enzyme among the NOSs, although the three NOSs have been shown to be involved in various inflammation-related diseases (26) . Recently, it was demonstrated that, in dogs with D. farinae-induced atopic dermatitis, eNOS was strongly expressed along with iNOS, NADPH oxidase 4 (NOX4), transforming growth factor-β1 (TGF-β1), COX-2 and myeloperoxidase (MPO), suggesting that these molecules are crossly associated with the cascade for the metabolic pathway (27) . It has been reported that eNOS and iNOS are expressed in skin biopsies of patients with atopic dermatitis (28) . On the other hand, in another study on colitis, eNOS-transgenic mice exhibit lower weight loss, less mortality, less inflammationinduced damage, les colonic myeloperoxidase activity and a lower expression of tumor necrosis factor-α compared to WT mice (29) . Therefore, the study of eNOS expression has yielded conflicting results; however, there seems to be a lower expression of eNOS with a less active inflammatory response, which are taken together with our data on Fig. 3B .
Asthma is very similar to atopic dermatitis by comparison of the molecular mechanisms and symptoms. In a previous study, NOS-deficient mice were treated with ovalbumin to induce airway inflammation, and thereafter airway hyperresponsiveness was evaluated using methacholine response. In that study, the iNOS-deficient mice exhibited similar results to the WT mice, but the nNOS-deficient mice exhibited significantly less airway responsiveness than the WT mice (30) . Overall, these data suggest that NOSs are major factors inatopic dermatitis; we confirmed that eNOS, as opposed to iNOS, was a more critical controlling factor in atopic dermatitis-related symptoms.
afAc/Gl downregulates MMP expression in vitro.
We then also used RAW264.7 cells to prove which molecular target(s) is regulated by the fraction. Anti-inflammatory effects can be examined by NO production, which was induced by LPS (500 ng/ml). As a result, no toxicity was observed from all samples by the MTT assay. The afAc/Gl (most potent inhibitory activity at 100 µg/ml) inhibited NO activity more significantly compared with Ac (69% inhibitory activity), although Gl had no significant effect (Fig. 4A, compare bars 6-9) .
MMPs are also a family of zinc-dependent enzymes that regulate the extracellular matrix as key factors in inflammation and disease (31) . We found that afAc/Gl extract regulated the expression of MMP-2, -7, -9, -12, -14 and -19 in RAW264.7 cells; however, Ac had a lesser effect on MMP expression compared toafAc/Gl, even though Ac significantly decreased MMP-9 expression (Fig. 4B) . MMP-1a-MMP-29 have been shown to be expressed in various cell lines, indicating that these proteases are associated with inflammatory events in various cell populations. Among these, MMP-2 and -9 have been shown to be associated with allergic inflammation (32) . A previous study demonstrated that MMP-2 was expressed in cells by afAC/Gl. RAW264.7 cells were treated with sample extract (10 µg/ml) for 5 h, and then exposed to LPS (1 µg/ml) for 4 h. Relative intensity of the PCR band was calculated as described in the Materials and methods. the epidermis and dermis from patients with atopic dermatitis, while MMP-9 was not upregulated (33) . However, another study demonstrated that MMP-9 was upregulated in a mouse model of DNFB-induced atopic dermatitis, and the IL-31 and T-bet gene were also expressed in the ear epidermis (34) . MMP-2 and -12 have been shown to be upregulated in the lung by inspiratory resistive breathing (35) . Another study demonstrated that the mRNA levels of MMP-1, MMP-7, MMP-10, Figure 5 . HPLC analysis of Ac and aqueous fraction produced by solid fermentation of Ganoderma lucidum on Artemisia capillaris (afAc/Gl). Sample extract (10 µg/ml) was used for treatment as described in the Materials and methods. Caffeic acid and chlorogenic acid were used as standard materials for HPLC. MMP-14 and MMP-19 were increased independently of COX-2 in monocytes stimulated with LPS (36) . Therefore, our results on the MMP regulation pattern imply that afAc/Gl exerts potent effects against atopic dermatitis via the inhibition MMP-2, -7, -9, -12, -14 and -19. Moreover, in a previous study, MMP-9-knockout mice exhibited increased levels of IL-4, and IL-13 in lung tissue, as shown by immunohistochemical analysis (37) , resulting in an increase in eosinophil and neutrophils counts in bronchioalveolar lavage fluid from MMP-9 knockout mice. MMP-2 knockout mice have been shown to exhibit increased asthmatic symptoms and asphyxiation induced by allergens (38) . Moreover, MMP-19-deficient mice have been shown to exhibit exacerbated eosinophilic inflammation in bronchoalveolar lavage fluid and bronchial tissue following allergen challenge (39) . Thus, these data indicate that some MMPs are critical to the maintenance of lung tissue, and may protect against asthmatic symptoms. Therefore, MMPs are not only upregulated by allergic inflammation, but also maintaine tissue-specific metabolism in the lungs. Further investigations on the role of MMPs in atopic dermatitis or asthma are warranted in order to develop appropriate curative therapy and/ or of preventive food ingredients.
HPLC analyses of afAc/Gl. The protective effects of the Ac extract (70% ethanol) against atopic dermatitis have previously been reported (11) . Ac contains potent compounds as anti-atopic or inflammatory constituents, such as hyperoside, isoquercetrin, chlorogenic acid, isochlorogenic acid, caffeic acid and scoparone. Therefore, we investigated whether the solid fermentation process can enhance the anti-atopic activity by converting these compounds into more potent ingredients. Surprisingly, we found that the afAc/Gl extract did not show any peaks on the HPLC analysis sheet, although the Ac extract contained these compounds (Fig. 5) . Since the Gl mycelium weight was <5% in the afAc/Gl extract and the Gl extract showed no activity against atopic dermatitis, we predicted that the active compounds had increased following solid fermentation by converting the compounds, such as chlorogenic acid and caffeic acid. Taken together, these results strongly suggest that isolation and purification of converted compounds is effective, in that converted compound(s) can be used as anti-atopic agent(s), as well as cosmetic ingredient(s) without any toxicity.
In conclusion, the solid fermentation of the Ac extract with Gl enhanced the anti-inflammatory effects on atopic dermatitis. In mice with DNFB-induced atopic dermatitis, treatment with afAc/Gl led to a 32% decrease in ear thickness, and a decrease in eosinophil number of 74%, which was approximately 2-7-fold more effective than the Ac extract without fermentation. Additionally, the numbers of iNOS-and eNOS-positive cells were decreased by treatment with afAc/Gl, as shown by immunohistochemical analysis. The afAc/Gl extract was more effective than Ac on NO inhibition, as well as on the inhibition of MMP-2, -7, -9, -12, -14 and -19 mRNA expression in RAW264.7 cells. As shown by HPLC analysis, we found that the Ac extract contained caffeic acid, catechin and chlorogenic acid, while the afAc/Gl extract did not. Taken together, we hypothesized that these and other polyphenolic compounds had been changed into novel biomaterial(s) with anti-inflammatory potential by solid fermentation, although we aim to perform further investigations to identify the specific anti-inflammatory ingredient(s) in the afAc/Gl extract. Importantly however, we demonstrate that solid fermentation is an innovative technology for the enhancement of bioconversion during the processing of natural products.
